Carcinoma, Transitional Cell: all 725 studies
Page 5 of 8. Open to participants first (201), then studies with results posted, then the rest; newest registration first within each.
- Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT05581004Phase 1
- Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline TherapyWithdrawnNCT05574504Phase 2
- Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnNCT05564416Phase 2
- Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsActive, not recruitingNCT05544552Phase 1/2
- A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)CompletedNCT05524545Phase 1
- PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell CarcinomasCompletedNCT05522257Not applicable
- A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary BladderStatus unknownNCT05503563
- A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnNCT05496192Phase 2
- Pembrolizumab in Muscle-invasive Bladder CancerActive, not recruitingNCT05406713Phase 2
- Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid TumorsWithdrawnNCT05338580Phase 2
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial CarcinomaActive, not recruitingNCT05335941Phase 2
- A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial CarcinomaStatus unknownNCT05318339Phase 2
- Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerActive, not recruitingNCT05239624Phase 2
- A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsWithdrawnNCT05234606Phase 1/2
- Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder CancerCompletedNCT05226117Phase 2
- Neoadjuvant Nivolumab for Upper Tract Urothelial CarcinomaStatus unknownNCT05160285Phase 2
- Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial CarcinomaCompletedNCT05154994Phase 1
- Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial CarcinomaStatus unknownNCT05139134
- A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderActive, not recruitingNCT05137262Phase 2
- A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)TerminatedNCT05121948Phase 1
- Study of MRx0518 and Avelumab in Patients With Urothelial CarcinomaWithdrawnNCT05107427Phase 2
- A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547Status unknownNCT05086666Phase 1/2
- Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOActive, not recruitingNCT05078047Phase 3
- Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian PopulationCompletedNCT05070039Not applicable
- Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving ErdafitinibTerminatedNCT05052372
- Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer PatientsCompletedNCT05046665Phase 1
- Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial CarcinomaStatus unknownNCT05030077Phase 2
- En Bloc TURBT With Collins Loop vs Conventional TURBTStatus unknownNCT05027412Not applicable
- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT05014139Phase 1
- Phase I BLASST-3 TrialWithdrawnNCT04972253Phase 1
- A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid TumoursActive, not recruitingNCT04969835Phase 1
- Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
- Glycosylation of Exosomes in Prostate and Urothelial CarcinomaTerminatedNCT04960956
- ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
- Efficacy and Utility of Cxbladder Tests in Hematuria PatientsCompletedNCT04943380
- Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid TumorsCompletedNCT04902872Phase 1/2
- Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the BladderStatus unknownNCT04878250Phase 2
- Prognostic Biomarkers in Patients With Urothelial CarcinomaCompletedNCT04872036
- Pre-operative Immunotherapy in Stage II-III Urothelial CancerCompletedNCT04871594Phase 1
- Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial CarcinomaStatus unknownNCT04871334Phase 1
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2
- Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaActive, not recruitingNCT04848519Phase 2
- A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium CancerStatus unknownNCT04839510Phase 2
- CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and BloodActive, not recruitingNCT04811846Not applicable
- A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid TumorsCompletedNCT04773951Phase 1
- Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic CharacteristicStatus unknownNCT04770974
- Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder CancerStatus unknownNCT04740866Not applicable
- Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck StudyStatus unknownNCT04702347
- Cryoablation With Pembrolizumab Or Avelumab In Urothelial CarcinomaCompletedNCT04701918Phase 2
- Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial CarcinomaCompletedNCT04672330Phase 2
- Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial CarcinomaStatus unknownNCT04672317Phase 2
- LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT04666688Phase 1/2
- CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
- Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.CompletedNCT04647981
- A Phase Ⅱ Study of F520 in Patients With Urothelial CarcinomaStatus unknownNCT04636515Phase 2
- A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial CarcinomaStatus unknownNCT04603846Phase 1
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingNCT04579224Phase 3
- Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2
- A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial CarcinomaWithdrawnNCT04568304Phase 3
- Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial CarcinomasCompletedNCT04566029
- Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder CancerCompletedNCT04553939Phase 2
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various CancersActive, not recruitingNCT04459273Phase 1
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-upStatus unknownNCT04432909
- DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1
- A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma PatientsStatus unknownNCT04383067Phase 2
- Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsCompletedNCT04344795Phase 1
- Investigating Marrow Infiltrating Lymphocytes in Renal Cell CarcinomaTerminatedNCT04341740Not applicable
- Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial CarcinomaCompletedNCT04314245
- Vasculogenic Mimicry in Urothelial CarcinomaStatus unknownNCT04295967
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
- A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial CancerStatus unknownNCT04264936Phase 1/2
- A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersTerminatedNCT04260802Phase 1/2
- A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphovascular InvasionStatus unknownNCT04255771Phase 3
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingNCT04235777Phase 1
- Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility StudyStatus unknownNCT04223063Not applicable
- A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial CarcinomaStatus unknownNCT04211012Phase 2
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaCompletedNCT04200963Phase 1
- Biological Effect of Vitamin D in Patients With Urothelial CarcinomaCompletedNCT04197089Phase 4
- Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint InhibitorWithdrawnNCT04179110Phase 2
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Phase 1/2
- Breathomics as Predictive Biomarker for Checkpoint Inhibitor ResponseCompletedNCT04146064
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
- An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial CarcinomaApproved for marketingNCT04136808
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1
- Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography UrographyActive, not recruitingNCT04113603Not applicable
- Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial CarcinomaStatus unknownNCT04099589Phase 2
- A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial CancerCompletedNCT04073602Phase 2
- Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionWithdrawnNCT04064190Phase 2
- Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial CarcinomaTerminatedNCT04047693Phase 2
- Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT04007744Phase 1
- Efficacy and Safety of UGN-101 in Recurrent PatientsWithdrawnNCT04006691Phase 3
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial CarcinomaActive, not recruitingNCT04004442Phase 1
- Application of UCAD for Diagnosing Urothelial Carcinoma.Status unknownNCT03998371
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)CompletedNCT03980041Phase 2
- Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaActive, not recruitingNCT03967977Phase 3
- Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based ChemotherapyCompletedNCT03945084Phase 2
- Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyWithdrawnNCT03935347Phase 2